PureTech to Present at Jefferies 2019 London Healthcare Conference
13 Noviembre 2019 - 1:00AM
Business Wire
PureTech Health plc (LSE: PRTC) (“PureTech”), a clinical-stage
biotechnology company dedicated to discovering, developing and
commercializing highly differentiated medicines for devastating
diseases, today announced that Daphne Zohar, founder and chief
executive officer, will present at the Jefferies 2019 London
Healthcare Conference on Wednesday, November 20, at 3:20PM GMT. A
webcast of the presentation will be available at
http://puretechhealth.com/investors under the Reports and
Presentations tab.
About PureTech PureTech is a clinical stage biotechnology
company dedicated to discovering, developing and commercializing
highly differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders, and inflammatory and
immunological diseases, among others. The Company has created a
broad and deep pipeline through the expertise of its experienced
research and development team and its extensive network of
scientists, clinicians and industry leaders. This pipeline, which
is being advanced both internally and through PureTech’s
affiliates, is comprised of 24 product candidates and one product
that has been cleared by the U.S. Food and Drug Administration
(FDA). All of the underlying programs and platforms that resulted
in this pipeline of product candidates were initially identified or
discovered and then advanced by the PureTech team through key
validation points based on the Company’s unique insights into the
biology of the brain, immune, and gut, or BIG, systems and the
interface between those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191112006078/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com U.S. media Tom Donovan +1 857 559
3397 tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024